SEARCH LISTED COMPANY

Any AUS or NZ company

BROWSE

Browse Australian delisted companies

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Browse terminated Australian managed funds

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
SEARCH PRIVATE COMPANY

SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

ESENSE-LAB LTD (ESE)

Click here for free access to this company's:
ASX, Legal & CGT Status

SHARE PRICES

(updated at weekends)

Former (or subsequent) names

 

Shareholder links

Our website ranking of ESE: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:
Link Market Services, Level 12 QV1 Building 250 St Georges Terrace Perth WA 6000
Tel : +61 8 9211 6670 or 1300 554 474
Fax : +61 2 9287 0303
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000ESE9
Address: Suite 6, 295 Rokeby Road Subiaco, Western Australia 6008
Tel:  +61 8 6555 2950 Fax: +61 8 6166 0261

Date first listed: 14/02/2017
Company Secretary: Erlyn Dale, Winton Willesee
Sector: Pharmaceuticals, Biotechnology & Life Sciences
Industry Group: 
Activities: Technology and research and development in the creation of virtual plants

delisted at entity's request per Listing Rule 17.11

11/08/2021

we understand this company all but failed with its securities unquoted for more than a year - it has now determined that as an unlisted entity it would be better able to raise funds and avoid ongoing listing costs

11/08/2021

The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report.

30/07/2021

The company releases a notice of proposed issue of securities - ESE.

02/07/2021

The company's AGM will be held at Quest South Perth Foreshore, 22 Harper Terrace, South Perth, Western Australia, 6151 on Friday, 6 August 2021 at 1:30pm (Australian Western Standard Time).

01/07/2021

The Company has formally applied to be removed from the official list under ASX Listing Rule 17.11. Following comprehensive consideration, the Board of the Company determined that the removal of the Company from the Official List is in the best interests of security holders.

25/06/2021

The company releases a notification regarding unquoted securities - ESE.

25/06/2021

The company releases a notification of cessation of securities - ESE.

23/06/2021

2,000,000 Restricted Shares issued to a trustee and held on trust for former Chief Executive Officer, Mr Itzik Mizrahi (under his employment agreement), have been forfeited in accordance with the terms of their issue. 2,000,000 CDIs had inadvertently been issued over the Restricted Shares, and have been cancelled, and the underlying Restricted Shares have been returned to the Company to be held as dormant shares.

21/06/2021

The company lodges its Quarterly Activities Report and Appendix 4C.

30/04/2021

The company releases a Corporate Governance Statement and Appendix 4G.

26/03/2021

The company lodges its Full Year Statutory Accounts.

26/03/2021

The company lodges its Preliminary Final Report.

01/03/2021

The company lodges its Quarterly Activities Report and Appendix 4C.

29/01/2021

The company has entered into loan note agreements with a number of sophisticated and professional investors to raise $812,000 to meet operational expenditure and fund working capital requirements. The loan notes are unsecured and carry an interest rate of 12% per annum, which is payable in cash on the repayment date. Funds raised will be used to meet operational expenditure, costs of the offer, outstanding liabilities, and to provide working capital to progress the development of the company's sanitiser products.

29/12/2020

The company releases an Investor Presentation.

09/12/2020

Testing of eSense's two proprietary blend terpene profiles, TRP-ENV and TRP-COV, was undertaken to determine their anti-viral activity against HCoV-OC43 Corona strain virus in a range of formulas. HCoV-OC43 is a weak strain of human corona virus which represents an accepted surrogate to evaluate activity of substances against SARS-CoV-2. "¢ Results have shown that certain formulas containing eSense's proprietary terpene blends are effective at neutralising HCoV-OC43 viruses showing a significant log reduction in viral copy numbers with a neutralization efficiency at least as good as 70% ethanol. Based on the results, eSense-Lab plans to realise the Letter of Intent with SeaLaria, with the intention to commercialise an alcohol-free sanitiser comprising TRP-ENV and SeaLaria's red algae.

27/11/2020

The company lodges its Quarterly Activities Report and Appendix 4C.

03/11/2020

The company lodges its Appendix 4D and Half Year Accounts.

01/09/2020

eSense has signed a research agreement with the Israeli Ministry of Health to commence a joint research project at the Central Virology lab located in the Chaim Sheba Medical Centre, the largest hospital in Israel, to test its proprietary TRP-ENVTM compound. The aim of the research project is to test TRP-ENV's efficacy against human coronavirusstrain termed OC43, that will be used as a model for SARS COV2, and will provide further research into terpenes' anti-viral qualities to reduce the ethanol content in sanitisers. Results will be relevant to previously announced projects with Wise Wine and SeaLaria. Tests will be conducted in stages with final results expected by November 2020. Approval for eSense to conduct these tests was granted by the MOH following several months of discussion with the Israeli central virologly lab of the MOH.

31/08/2020

The company has become aware, following ASX queries, that it has not been in compliance with. In relation to Article 34 of the Articles of Association, the Company is pleased to confirm that the Company's joint company secretary, Mr Winton Willesee, has agreed to be appointed as an interim non-executive director of the Company, effective immediately. In relation to the Company not having the required number of "˜External Directors', the Companies Law requires the Company call a shareholders' meeting as soon as possible to appoint replacement External Directors. The Company intends to call a shareholders' meeting as soon as possible to consider the appointment of 2 new External Directors. ASX will require the Company's securities to remain in suspension until the conditions mentioned above are satisfied. The Company is also advancing its commercialisation efforts and accelerating the current business plan.

31/07/2020

The company lodges its Quarterly Activities Report and Appendix 4C.

31/07/2020

The securities of eSense-Lab Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of ESE, pending the release of an announcement regarding ASX's queries in relation to ESE's board composition and an announcement regarding a research agreement.

27/07/2020

The suspension of trading in the securities of eSense-Lab Ltd will be lifted immediately following the release by ESE of an announcement regarding capital raising.

14/04/2020

The company completes $1.145 million capital raising. $250,000 in Loan Notes issued to Sophisitcated Investors. Secures firm commitments from Sophisitcated Investors for a placement of securities to raise an additional $895,000 (conditional on shareholder approval).

14/04/2020

The voluntary suspension is to last until the earlier of the company releasing an announcement regarding the capital raising or prior to commencement of trading on Tuesday, 14 April 2020.

09/04/2020

The securities of eSense-Lab Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of ESE, pending the release of an announcement regarding a capital raising.

07/04/2020

The suspension of trading in the securities of eSense-Lab Ltd will be lifted from the commencement of trading on Thursday, 3 May 2018, following release of the Company's quarterly reports and receipt of satisfactory responses to ASX queries.

02/05/2018

The company lodges its Quarterly Activities & Appendix 4C Cashflow Report.

30/04/2018

The company releases its Appendix 4G and Corporate Governance Statement.

04/04/2018

MMJ PhytoTech Limited notes that the shareholders of e-Sense Lab have not approved the issuance to MMJ of free options to acquire 1.25 million ordinary shares of e-Sense at $0.30 per share. Accordingly, under the terms of the placement of 2.5 million ordinary shares to MMJ by e-Sense in November 2017, e-Sense is to pay $199,000 to MMJ in consideration for those unapproved options.

03/04/2018

The company releases the results of its AGM and EGM.

03/04/2018

The company lodges its Full Year Statutory Accounts.

29/03/2018

The company releases the Chairman's Address to Shareholders.

29/03/2018

The company issues a response to ASX query.

29/03/2018

The company issues a response to ASX Query.

28/03/2018

The securities of eSense-Lab Limited will be suspended from official quotation immediately pursuant to Listing Rule 17.3.

23/03/2018

listed entity carried for record purposes only

14/02/2017

ASX Announcements (courtesy of ASX)

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.
Loading comments....  Most recent comments

What happens to our shares now you have delisted? 

25/08/2021 21:41:20

How do I sell ese

23/08/2021 13:07:44

how can i sale my share if company delisted from ASX

13/08/2021 17:03:57

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box. If an image appears, enter the word/figures you see in the image.

    loading Posting your comments. Please wait...

    Directors' on-market share transactions (last 5)

     

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    James EllingfordNon Exec Chairman13/01/2020
    Yoav ElishoovCEO07/12/2020
    Peter HatfullNon Exec Director02/07/2020
    Winton WilleseeNon Exec Director31/07/2020

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Itzik MizrahiCEO09/03/202007/12/2020
    Benjamin KarasikDirector09/02/201831/10/2020
    Piers LewisNon Exec Director30/11/201802/07/2020
    Amit EdrNon Exec Director30/11/201809/06/2020
    Michael EdwardsNon Exec Director08/11/201927/03/2020
    Haim CohenDirector01/10/201630/01/2020
    Galit AsafNon Exec Director05/12/201608/11/2019
    Kobi ZechariaNon Exec Director30/05/201820/12/2018
    Ilan SaadChairman01/10/201611/05/2018
    Eran GilboaNon Exec Director19/09/201611/05/2018
    Quentin MegsonNon Exec Director05/12/201629/03/2018
    Brendan de KauweDirector01/10/201629/03/2018

    Date of first appointment, title may have changed.